EPIX is currently conducting clinical trials for Alzheimer's disease. For more information, please visit http://www.trialforad.com.

For information about the PRX-03140 Phase 2a data, please call 866-514-2901.

June 3, 2009
EPIX Pharmaceuticals Announces Noteholders' Right to Require the Company to Repurchase $3.2 Million Outstanding Balance of 3% Convertible Senior Notes Due 2024

May 11, 2009
EPIX Pharmaceuticals Announces First Quarter 2009 Financial Results

May 5, 2009
EPIX Pharmaceuticals Announces Final Results of Exchange Offer for $100 Million Convertible Notes